Multiple Sclerosis Research Repository

 “Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis”: Brown JWL-Among patients with relapsing-remitting MS, initial treatment with fingolimod, alemtuzumab, or natalizumab was associated with a lower risk of conversion to secondary progressive MS vs initial treatment with glatiramer acetate or interferon beta.